Skip to main content
SpringerLink
Log in

Prognostic Factors in Uveal Melanoma

  • Chapter
  • First Online:
Book cover Clinical Ophthalmic Oncology

  • 835 Accesses

Abstract

Uveal melanomas are among the few cancers that, until recently, could be treated without examining tissue to confirm the clinical diagnosis and establish prognosis. The Collaborative Ocular Melanoma Study demonstrated that in patients with clear ocular media, clinical misdiagnosis of choroidal melanocytic neoplasms is extremely rare, so the need to confirm the diagnosis became less urgent. Also, after the Collaborative Ocular Melanoma Study determined that there was no significant difference in mortality between enucleation and vision-sparing radiation therapy, many patients elected to have their tumors ablated to preserve the affected eye, and in such cases, it was possible to begin treatment without examining any tissue to confirm the diagnosis or establish the prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Collaborative ocular melanoma study (COMOS) randomized trial of pre-enucleation radiation for large choroidal melanoma – II – initial mortality findings – COMS report no. 10. Am J Ophthalmol. 1998;126:622.

    Google Scholar 

  2. Damato B, Eleuteri A, Taktak AF, Coupland SE. Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res. 2011;30:285–95.

    Article  PubMed  Google Scholar 

  3. Shammas HF, Blodi FC. Prognostic factors in choroidal and ciliary body melanomas. Arch Ophthalmol. 1977;95:63–9.

    Article  CAS  PubMed  Google Scholar 

  4. Kaiserman I, Anteby I, Chowers I, Blumenthal EZ, Kliers I, Pe’er J. Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma. Br J Ophthalmol. 2004;88:892–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Kivela T, Kujala E. Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond. Eye (Lond). 2013;27:243–52.

    Article  CAS  Google Scholar 

  6. Augsburger JJ, Gamel JW. Clinical prognostic factors in patients with posterior uveal malignant melanoma. Cancer. 1990;66:1596–600.

    Article  CAS  PubMed  Google Scholar 

  7. Zloto O, Pe’er J, Frenkel S. Gender differences in clinical presentation and prognosis of uveal melanoma. Invest Ophthalmol Vis Sci. 2013;54:652–6.

    Article  PubMed  Google Scholar 

  8. Char DH, Kroll S, Phillips TL. Uveal melanoma: growth rate and progression. Arch Ophthalmol. 1997;115:1014–8.

    Article  CAS  PubMed  Google Scholar 

  9. Kaiserman I, Rosner M, Pe’er J. Forecasting the prognosis of choroidal melanoma with an artificial neural network. Ophthalmology. 2005;112:1608–11.

    PubMed  Google Scholar 

  10. Eleuteri A, Damato B, Coupland SE, Taktak AFG. Enhancing survival prognostication in patients with choroidal melanoma by integrating pathologic, clinical and genetic predictors of metastasis. Int J Biomed Eng Technol. 2012;8:18–35.

    Article  Google Scholar 

  11. Jakobiec FA, Silbert G. Are most iris ‘melanomas’ really nevi? A clinicopathologic study of 189 lesions. Arch Ophthalmol. 1981;99:2117–32.

    Article  CAS  PubMed  Google Scholar 

  12. Folberg R, Salomao D, Grossniklaus HE, Proia AD, Rao NA, Cameron JD. Recommendations for the reporting of tissues removed as part of the surgical treatment of common malignancies of the eye and its adnexa. Am J Surg Pathol. 2003;27:999–1004.

    Article  PubMed  Google Scholar 

  13. Gamel JW, McLean I, Greenberg RA, Naids RM, Folberg R, Augsburger JJ, Donoso LA, Seddon JM, Albert DM. Objective assessment of the malignant potential of intraocular melanomas with standard microslides stained with hematoxylin-eosin. Hum Pathol. 1985;16:689–92.

    Article  CAS  PubMed  Google Scholar 

  14. McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender’s classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol. 1983;96:502–9.

    CAS  PubMed  Google Scholar 

  15. Callender GR. Malignant melanotic tumors of the eye: a study of histologic types in 111 cases. Trans Am Acad Ophthalmol Otolaryngol. 1931;36:131–42.

    Google Scholar 

  16. McLean IW, Zimmerman LE, Evans RM. Reappraisal of Callender’s spindle A type of malignant melanoma of choroid and ciliary body. Am J Ophthalmol. 1978;86:557–64.

    CAS  PubMed  Google Scholar 

  17. McLean IW, Sibug ME, Becker RL, McCurdy JB. Uveal melanoma - the importance of large nucleoli in predicting patient outcome - an automated image analysis study. Cancer. 1997;79:982–8.

    Article  CAS  PubMed  Google Scholar 

  18. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson RF, Pe’er J, Gruman LM. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389–98.

    Article  CAS  PubMed  Google Scholar 

  19. McLean IW, Foster WD, Zimmerman LE. Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol. 1977;95:48–58.

    Article  CAS  PubMed  Google Scholar 

  20. Pe’er J, Gnessin H, Shargal Y, Livni N. PC-10 immunostaining of proliferating cell nuclear antigen (PCNA) in posterior uveal melanoma. Ophthalmology. 1994;101:56–62.

    Article  PubMed  Google Scholar 

  21. de la Cruz Jr PO, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990;65:112–5.

    Article  PubMed  Google Scholar 

  22. Lin AY, Maniotis AJ, Valyi-Nagy K, Majumdar D, Setty S, Kadkol S, Leach L, Pe’er J, Folberg R. Distinguishing fibrovascular septa from vasculogenic mimicry patterns. Arch Pathol Lab Med. 2005;129:884–92.

    PubMed  Google Scholar 

  23. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe’er J, Trent JM, Meltzer PS, Hendrix MJC. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155:739–52.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Clarijs R, Otte-Holler I, Ruiter DJ, de Waal RM. Presence of a fluid-conducting meshwork in xenografted cutaneous and primary human uveal melanoma. Invest Ophthalmol Vis Sci. 2002;43:912–8.

    PubMed  Google Scholar 

  25. Foss AJE, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S. Microvessel count predicts survival in uveal melanoma. Cancer Res. 1996;56:2900–3.

    CAS  PubMed  Google Scholar 

  26. Chen X, Maniotis AJ, Majumdar D, Pe’er J, Folberg R. Uveal melanoma cell staining for CD34 and assessment of tumor vascularity. Invest Ophthalmol Vis Sci. 2002;43:2533–9.

    PubMed  Google Scholar 

  27. Coupland SE, Lake SL, Zeschnigk M, Damato BE. Molecular pathology of uveal melanoma. Eye. 2013;27(2):230–42. doi:10.1038/eye.2012.255. Epub 2012 Dec 7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Augsburger JJ, Shields JA, Folberg R, Lang WR, O’Hara BJ, Claricci JD. Fine needle aspiration biopsy in the diagnosis of intraocular cancer cytologic-histologic correlations. Ophthalmology. 1985;92:39–49.

    Article  CAS  PubMed  Google Scholar 

  29. Char DH, Kroll SM, Stoloff A, Kaleta-Michaels S, Crawford JB, Miller TR, Howes Jr EL, Ljung BM. Cytomorphometry of uveal melanoma Comparison of fine needle aspiration biopsy samples with histologic sections. Anal Quant Cytol Histol. 1991;13:293–9.

    CAS  PubMed  Google Scholar 

  30. Maat W, Jordanova ES, van Zelderen-Bhola SL, Barthen ER, Wessels HW, Schalij-Delfos NE, Jager MJ. The heterogeneous distribution of monosomy 3 in uveal melanomas - Implications for prognostication based on fine-needle aspiration biopsies. Arch Pathol Lab Med. 2007;131:91–6.

    PubMed  Google Scholar 

  31. Schoenfield L, Pettay J, Tubbs RR, Singh AD. Variation of monosomy 3 status within uveal melanoma. Arch Pathol Lab Med. 2009;133:1219–22.

    PubMed  Google Scholar 

  32. Onken MD, Worley L, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn. 2010;12:461–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, Aaberg Jr TM, Altaweel MM, Bardenstein DS, Finger PT, Gallie BL, Harocopos GJ, Hovland PG, McGowan HD, Milman T, Mruthyunjaya P, Simpson ER, Smith ME, Wilson DJ, Wirostko WJ, Harbour JW. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119:1596–603.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Folberg R. The molecular classification of uveal melanocytic lesions an important discovery in context. J Mol Diagn. 2010;12:391–3.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Tschentscher F, Husing J, Holter T, Kruse E, Dresen IG, Jockel KH, Anastassiou G, Schilling H, Bornfeld N, Horsthemke B, Lohmann DR, Zeschnigk M. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 2003;63:2578–84.

    CAS  PubMed  Google Scholar 

  36. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64:7205–9.

    Article  CAS  PubMed  Google Scholar 

  37. Kadkol SS, Lin AY, Barak V, Kalickman I, Leach L, Valyi-Nagy K, Majumdar D, Setty S, Maniotis AJ, Folberg R, Pe’er J. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci. 2006;47:802–6.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Folberg R, Arbieva Z, Moses J, Hayee A, Sandal T, Kadkol S, Lin AY, Valyi-Nagy K, Setty S, Leach L, Chevez-Barrios P, Larsen P, Majumdar D, Pe’er J, Maniotis AJ. Tumor cell plasticity in uveal melanoma: microenvironment directed dampening of the invasive and metastatic genotype and phenotype accompanies the generation of vasculogenic mimicry patterns. Am J Pathol. 2006;169:1376–89.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Prescher G, Bornfeld N, Hirche H, Horsthemke B, J’ckel KH, Becher R. Prognostic impliations of monosomy 3 in uveal melanoma. Lancet. 1996;347:1222–5.

    Article  CAS  PubMed  Google Scholar 

  40. Schaller UC, Bosserhoff AK, Neubauer AS, Buettner R, Kampik A, Mueller AJ. Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res. 2002;12:593–9.

    Article  CAS  PubMed  Google Scholar 

  41. Barak V, Kaiserman I, Frenkel S, Hendler K, Kalickman I, Pe’er J. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1). Anticancer Res. 2011;31:345–9.

    CAS  PubMed  Google Scholar 

  42. Frenkel S, Zloto O, Pe’er J, Barak V. Insulin like Growth Factor-I as a predictive biomarker for metastatic uveal melanoma in humans. Invest Ophthalmol Vis Sci. 2013;54:490–3.

    Article  CAS  PubMed  Google Scholar 

  43. Triozzi PL, Elson P, Aldrich W, Achberger S, Tubbs R, Biscotti CV, Singh AD. Elevated blood beta-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma. Melanoma Res. 2013;23:1–7.

    Article  CAS  PubMed  Google Scholar 

  44. Triozzi PL, Singh AD. Blood biomarkers for uveal melanoma. Future Oncol. 2012;8:205–15.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oakland University William Beaumont School of Medicine, Rochester, MI, USA

    Robert Folberg MD

  2. Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

    Jacob Pe’er MD

Authors
  1. Robert Folberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacob Pe’er MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacob Pe’er MD .

Editor information

Editors and Affiliations

  1. Ocular Oncology Service, Departments of Ophthalmology and Radiation Oncology, University of California, San Francisco, San Francisco, California, USA

    Bertil Damato

  2. Dept. of Ophthalmic Oncology, Cole Eye Institute Cleveland Clinic Foundation, Cleveland, Ohio, USA

    Arun D. Singh

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Folberg, R., Pe’er, J. (2014). Prognostic Factors in Uveal Melanoma. In: Damato, B., Singh, A. (eds) Clinical Ophthalmic Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54255-8_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54255-8_19

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54254-1

  • Online ISBN: 978-3-642-54255-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation